Your browser is no longer supported. Please, upgrade your browser.
Settings
CYCN Cyclerion Therapeutics, Inc. daily Stock Chart
CYCN [NASD]
Cyclerion Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.49 Insider Own1.70% Shs Outstand27.09M Perf Week14.02%
Market Cap81.54M Forward P/E- EPS next Y-1.04 Insider Trans17.18% Shs Float24.26M Perf Month-28.50%
Income-123.00M PEG- EPS next Q-0.87 Inst Own58.80% Short Float7.98% Perf Quarter12.73%
Sales4.50M P/S18.12 EPS this Y-6.80% Inst Trans-19.62% Short Ratio3.06 Perf Half Y-78.39%
Book/sh3.57 P/B0.84 EPS next Y48.30% ROA-76.70% Target Price5.00 Perf Year-84.16%
Cash/sh3.50 P/C0.86 EPS next 5Y- ROE-140.40% 52W Range1.69 - 22.85 Perf YTD10.66%
Dividend- P/FCF- EPS past 5Y- ROI-128.00% 52W High-86.83% Beta-
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low78.11% ATR0.58
Employees94 Current Ratio5.50 Sales Q/Q- Oper. Margin- RSI (14)45.45 Volatility20.67% 17.09%
OptionableYes Debt/Eq0.00 EPS Q/Q15.60% Profit Margin- Rel Volume0.20 Prev Close3.25
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume633.27K Price3.01
Recom3.00 SMA20-9.93% SMA50-18.70% SMA200-55.21% Volume127,505 Change-7.38%
Jun-03-19Initiated Credit Suisse Neutral
Mar-23-20 06:50AM  Are Insiders Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Stock? Simply Wall St. +18.94%
Jan-13-20 07:00AM  Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases GlobeNewswire +10.26%
Jan-12-20 05:05PM  The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO Benzinga
Dec-24-19 08:17AM  Can Cyclerion Therapeutics (NASDAQ:CYCN) Afford To Invest In Growth? Simply Wall St. +6.87%
Dec-23-19 07:00AM  Cyclerion to Present at the J.P. Morgan Healthcare Conference GlobeNewswire
Dec-12-19 03:43PM  Cyclerion Therapeutics, Inc. (CYCN) Is Burning These Hedge Funds Insider Monkey
Nov-27-19 07:00AM  Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference GlobeNewswire
Nov-01-19 10:52AM  Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View Zacks
Oct-31-19 08:08AM  The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut Benzinga -13.09%
Oct-30-19 09:24AM  Cyclerion's stock plummets to pace premarket losers after diabetes treatment study missed primary endpoint MarketWatch -79.52%
08:17AM  Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial American City Business Journals
07:31AM  Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy GlobeNewswire
07:30AM  Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF) GlobeNewswire
Oct-08-19 08:00AM  Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings GlobeNewswire
Sep-25-19 01:22PM  Read This Before Selling Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares Simply Wall St.
Sep-10-19 08:00AM  Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17 GlobeNewswire
Aug-12-19 08:00AM  Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months GlobeNewswire -5.45%
Jul-31-19 10:58AM  Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates Zacks
Jul-24-19 03:23PM  What Kind Of Shareholders Own Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)? Simply Wall St. -5.39%
Jun-11-19 08:30AM  Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP GlobeNewswire
Jun-05-19 09:50AM  Ironwood Initiates Dosing in Mid-Stage Study for MD-7246 Zacks -6.64%
Jun-04-19 01:58PM  3 Spinoff Stocks Worth Your Attention GuruFocus.com
08:30AM  Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings GlobeNewswire
May-13-19 07:00AM  Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company GlobeNewswire -9.38%
Apr-25-19 08:00AM  Cyclerion to Host Corporate Overview Call on May 13, 2019 GlobeNewswire
Apr-09-19 05:37AM  Cyclerion taps ex-Shire exec as chief innovation officer American City Business Journals +8.16%
Apr-02-19 08:00AM  Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases GlobeNewswire -36.59%
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Huyett WilliamChief Financial OfficerFeb 21Sale5.123,55918,22271,417Feb 25 04:11 PM
Currie Mark GPresidentDec 30Sale2.4825,00062,000271,755Dec 31 05:55 PM
Currie Mark GPresidentDec 27Sale2.5525,00063,750296,755Dec 31 05:55 PM
Busch AndreasChief Innovation OfficerNov 15Buy1.82125,000227,500125,000Nov 19 04:02 PM
Huyett WilliamChief Financial OfficerNov 08Sale2.053,9228,04074,976Nov 12 04:26 PM